Virus Del Papiloma Humano (Vph)

v

1699

Human papilloma virus (HPV) vaccine
See also Vaccines

3. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle StudyInvestigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645–51.

General Information
Cervical cancer is the second most common cause of cancer deaths inwomen worldwide and the number one cause in the developing world. It is almost invariably associated with HPV infection. HPV type 16 is found in about 50% of cervical cancers. About 70% of cervicalcancers are associated with HPV types 16, 18, and 8 other HPV types. Types 18, 31, and 45 account for 25% of HVP-positive tumors. HPV types 6 and 11 can cause genital warts. The development of a safe andeffective HPV vaccine could prevent premalignant and malignant disease associated with HPV infection. Various HPV vaccines are under development or are undergoing clinical trials. Among others,GlaxoSmithKline (bivalent HPV types 16 and 18) and Merck (HPV types 6, 11, 16, 18) are both conducting expanded phase III trials and the researchers say the results so far have been promising. Merck plans toapply for approval to the US Food and Drug Administration in late 2005. Clinical studies with a recombinant vaccine (using Vaccinia virus expressing HPV 16, 18, E6, and E7 proteins) in patients withpreinvasive and invasive cancer have been reviewed (1). Observational studies There has been a trial of a papilloma (HPV-16) virus-like particle vaccine in 72 healthy volunteers, aged 18–27 years (2).The vaccine was well tolerated and highly immunogenic. Placebo-controlled studies In a double-blind study in 2392 young women (aged 16–23 years) randomly assigned to either three doses of placebo orHPV-16 vaccine at day 0, month 2, and month 6, the vaccine reduced the incidence of both HPV-16 infection (3.8 per 100 woman-years at risk in the placebo group versus 0 per 100 woman-years at risk in...